Press release from PR Newswire
Hologic to Participate in Three Investor Conferences
Monday, May 09, 2011
Hologic to Participate in Three Investor Conferences07:00 EDT Monday, May 09, 2011BEDFORD, Mass., May 9, 2011 /PRNewswire/ -- Hologic, Inc. (NASDAQ: HOLX) today announced that company management will participate in the following conferences:Glenn Muir, Executive Vice President and Chief Financial Officer, will present at the Jefferies 2011 Global Healthcare Conference in New York City, New York on Tuesday, June 7, 2011, at 9:00 a.m. (Eastern). Rob Cascella, President and Chief Executive Officer, will present at the Goldman Sachs 32nd Annual Global Healthcare Conference in Rancho Palos Verdes, California on Tuesday, June 7, 2011, at 5:40 p.m. (Eastern). Deborah Gordon, Vice President of Investor Relations, will host investor meetings at the Lazard Capital Markets Medical Technology and Healthcare Services Conference in Mashantucket, Connecticut on Monday, June 20, 2011. Management will not be presenting at this conference.Interested parties are invited to listen to the live audio webcasts of the investor presentations on the investor section of Hologic's website at www.hologic.com/investors-overview. Archives of the presentations will be available for replay following the conferences.About Hologic, Inc.Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, breast Magnetic Resonance Imaging, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia and uterine fibroids, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications. For more information, visit www.hologic.com.Contact:Deborah GordonVice President, Investor RelationsHologic, Inc.(781) 999-7716SOURCE Hologic, Inc.